Astellas Pharma announced a pharma alliance with an investigator at Harvard Medical School focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets.
Astellas and Harvard will work with the aim to provide a new treatment option with a view of a gene therapy, to retinitis pigmentosa patients who have difficulty maintaining good vision.
This collaborative research will be led by Constance L. Cepko, Ph. D., Professor of Genetics and of Ophthalmology at Harvard, who is also an investigator of the Howard Hughes Medical Institute, and is a world-renowned authority on ophthalmology and gene therapy.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Astellas Pharma
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity